FDA approves Cabometyx for differentiated thyroid cancerNov 10Regulatory decisioncabozantinibExelixis
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Arcus files preliminary prospectus supplement, cites new casdatifan ccRCC dataOct 21Clinical readoutArcus Biosciences, Inc.casdatifanUpdated
BMS registers Phase 1 CAR T cell trial in kidney cancer; adds mavacamten real-world studyOct 1Weekly roundup, 5 itemsBristol Myers SquibbgolcadomideUpdated
Kura Oncology posts $9.1 million in KOMZIFTI revenue in second quarter of 2026Aug 12Quarterly updateKura Oncology, Inc.ziftomenib
Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026Aug 5Quarterly updateArcus Biosciences, Inc.AstraZeneca
Exelixis Q2 2026 results detail zanzalintinib pipeline progress, narrows guidanceAug 5Quarterly updateExelixisMerck & Co., Inc.